Form 4: Ovid Therapeutics Director Kevin Fitzgerald Granted 45,000 Stock Options

Ovid Therapeutics Inc. Director Kevin Joseph Fitzgerald was granted 45,000 stock options with an exercise price of $0.57, vesting in full on February 20, 2026.

Summary

• Kevin Joseph Fitzgerald, a Director of Ovid Therapeutics Inc. (OVID), was granted 45,000 stock options.
• The options have an exercise price of $0.57 per share.
• These options will vest in full on February 20, 2026, contingent upon Mr. Fitzgerald's continuous service to the company.
• The expiration date for these options is February 19, 2035.
• Following this transaction, Mr. Fitzgerald beneficially owns 45,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive for aligning interests, but it's a routine compensation event and not indicative of significant operational news.

Positives

• The grant of 45,000 stock options to Director Kevin Joseph Fitzgerald aligns his interests with those of shareholders, incentivizing long-term company performance.
• The exercise price of $0.57 provides a clear benchmark for future stock performance relative to the grant.

Negatives

• No negative information is typically disclosed in a Form 4 filing, which primarily reports changes in beneficial ownership.

Risks

• The value of the granted stock options is subject to the future market price of Ovid Therapeutics Inc. common stock; if the stock price does not exceed the $0.57 exercise price, the options may expire worthless.

Future Outlook

The stock options granted to Director Kevin Joseph Fitzgerald are set to vest in full on February 20, 2026, contingent on his continued service, indicating a future milestone for his equity compensation.

Industry Context

This Form 4 filing represents a routine insider transaction, specifically an equity grant, which is a common compensation practice across all industries, including the biotechnology and pharmaceutical sectors where Ovid Therapeutics operates, to align management and director incentives with shareholder value.

Related Party Transactions

• The grant of 45,000 stock options to Kevin Joseph Fitzgerald, a Director of Ovid Therapeutics Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the director's financial interests with those of shareholders, potentially encouraging decisions that enhance long-term stock value.
• Employees: While not directly impacting all employees, such grants are part of a broader compensation strategy that can influence overall company culture and retention of key personnel.

Next Steps

• The 45,000 stock options are scheduled to vest in full on February 20, 2026, provided the reporting person maintains continuous service.

Key Dates

Keywords

Ovid Therapeutics, OVID, SEC Form 4, Insider Transaction, Stock Options, Director Compensation, Beneficial Ownership, Equity Grant